Nutrition & Metabolism | |
Allantoin activates imidazoline I-3 receptors to enhance insulin secretion in pancreatic β-cells | |
Kao-Chang Lin2  Juei-Tang Cheng5  Kun-Ming Chung3  Ho-Shan Niu4  Li-Jen Chen4  Cheng-Chia Tsai1  | |
[1] Department of Neurosurgery, Mackay Hospital, and Graduate Institute of Injury Prevention and Control, College of Medicine, Taipei Medical University, Taipei City 10361, Taiwan;Institute of Biotechnology, Southern Taiwan University, Tainan City, Yong Kang 71004, Taiwan;Department of Internal Medicine, Chi-Mei Medical Center, Yong Kang City, Tainan County 73101, Taiwan;Department of Nursing, Tzu Chi College of Technology, Hualien City 97005, Taiwan;Department of Medical Research, Chi-Mei Medical Center, Yong Kang City, Tainan County 73101, Taiwan | |
关键词: NISCH; CHO-K1; Imidazoline I3 receptor; Insulin secretion; Allantoin; | |
Others : 1228212 DOI : 10.1186/1743-7075-11-41 |
|
received in 2014-05-18, accepted in 2014-08-28, 发布年份 2014 | |
【 摘 要 】
Background
Imidazoline I3 receptors (I-3R) can regulate insulin secretion in pancreatic β-cells. It has been indicated that allantoin ameliorates hyperglycemia by activating imidazoline I2 receptors (I-2R). Thus, the effect of allantoin on I-3R is identified in the present study.
Methods
We used male Wistar rats to screen allantoin’s ability for lowering of blood glucose and stimulation of insulin secretion. Chinese hamster ovary-K1 cells transfected with imidazoline receptors (NISCH-CHO-K1 cells) were also applied to characterize the direct effect of allantoin on this receptor. Additionally, KU14R as specific antagonist was treated to block I-3R in rats and in the cultured pancreatic β-cells named Min 6 cells.
Results
In rats, allantoin decreased blood sugar with an increase in plasma insulin. Also, allantoin enhanced calcium influx into NISCH-CHO-K1 cells in a way similar to agmatine, an I-R agonist. Moreover, KU14R dose-dependently blocked allantoin-induced insulin secretion both in Min 6 cells and in Wistar rats.
Conclusion
Allantoin can activate I-3R to enhance insulin secretion for lowering of blood sugar in Wistar rats. Thus, allantoin may provide beneficial effects as a supplement for diabetic patients after clinical trials.
【 授权许可】
2014 Tsai et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20151011040124885.pdf | 495KB | download | |
Figure 4. | 60KB | Image | download |
Figure 3. | 65KB | Image | download |
Figure 2. | 59KB | Image | download |
Figure 1. | 83KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
【 参考文献 】
- [1]Sagara K, Ojima M, Suto K, Yoshida T: Quantitative determination of allantoin in Dioscorea rhizome and an Oriental pharmaceutical preparation, hachimi-gan, by high-performance liquid chromatography. Planta Med 1989, 55:93.
- [2]Shestopalov AV, Shkurat TP, Mikashinovich ZI, Kryzhanovskaia IO, Bogacheva MA, Lomteva SV, Prokof’ev VP, Gus’kov EP: Biological functions of allantoin. Izv Akad Nauk Ser Biol 2006, 541-545.
- [3]Sato K, Iemitsu M, Aizawa K, Ajisaka R: DHEA improves impaired activation of Akt and PKC zeta/lambda-GLUT4 pathway in skeletal muscle and improves hyperglycaemia in streptozotocin-induced diabetes rats. Acta Physiol (Oxf) 2009, 197:217-225.
- [4]Gao X, Li B, Jiang H, Liu F, Xu D, Liu Z: Dioscorea opposita reverses dexamethasone induced insulin resistance. Fitoterapia 2007, 78:12-15.
- [5]Hsu JH, Wu YC, Liu IM, Cheng JT: Dioscorea as the principal herb of Die-Huang-Wan, a widely used herbal mixture in China, for improvement of insulin resistance in fructose-rich chow-fed rats. J Ethnopharmacol 2007, 112:577-584.
- [6]Wang SJ, Liu HY, Gao WY, Chen HX, Yu JG, Xiao PG: Characterization of new starches separated from different Chinese yam (Dioscorea opposita Thunb.) cultivars. Food Chem 2006, 99:30-37.
- [7]Cheng JT, Niu CS, Chen W, Wu HT, Cheng KC, Wen YJ, Lin KC: Decrease of plasma glucose by Allantoin, an active principle of Yam (Dioscorea spp.), in streptozotocin-induced diabetic rats. J Agric Food Chem 2010, 58:12031-12035.
- [8]Dardonville C, Rozas I: Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med Res Rev 2004, 24:639-661.
- [9]Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, Johnson GG: I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci 1995, 763:22-42.
- [10]Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA: Imidazolines and pancreatic hormone secretion. Ann N Y Acad Sci 1999, 881:217-228.
- [11]Lui TN, Tsao CW, Huang SY, Chang CH, Cheng JT: Activation of imidazoline I2B receptors is linked with AMP kinase pathway to increase glucose uptake in cultured C2C12 cells. Neurosci Lett 2010, 474:144-147.
- [12]Cheng JT, Chang CH, Wu HT, Cheng KC, Lin HJ: Increase of beta-endorphin secretion by agmatine is induced by activation of imidazoline I(2A) receptors in adrenal gland of rats. Neurosci Lett 2010, 468:297-299.
- [13]Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP: ‘Seeing through a glass darkly’: casting light on imidazoline ‘I’ sites. Trends Pharmacol Sci 1998, 19:381-390.
- [14]Chan SL, Dunne MJ, Stillings MR, Morgan NG: The alpha 2-adrenoceptor antagonist efaroxan modulates K + ATP channels in insulin-secreting cells. Eur J Pharmacol 1991, 204:41-48.
- [15]Brown CA, Loweth AC, Smith SA, Morgan NG: Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br J Pharmacol 1993, 108:312-317.
- [16]Chan SL, Pallett AL, Clews J, Ramsden CA, Chapman JC, Kane C, Dunne MJ, Morgan NG: Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. Eur J Pharmacol 1998, 355:67-76.
- [17]Cheng JT, Lee JP, Chen W, Wu HT, Lin KC: Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats. Horm Metab Res 2011, 43:26-30.
- [18]Chung HH, Yang TT, Chen MF, Chou MT, Cheng JT: Improvement of hyperphagia by activation of cerebral I(1)-imidazoline receptors in streptozotocin-induced diabetic mice. Horm Metab Res 2012, 44:645-649.
- [19]Hwang SL, Liu IM, Tzeng TF, Cheng JT: Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats. Diabetologia 2005, 48:767-775.
- [20]Jou SB, Liu IM, Cheng JT: Activation of imidazoline receptor by agmatine to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci Lett 2004, 358:111-114.
- [21]Gongadze NV, Antelava NA, Kezeli TD: Imidazoline receptors. Georgian Med News 2008, 160–161:44-47.
- [22]Morgan NG, Chan SL: Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 2001, 7:1413-1431.
- [23]Baron AD: Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Res Clin Pract 1998, 40(Suppl):S51-S55.
- [24]Cheng JY, Whitelock J, Poole-Warren L: Syndecan-4 is associated with beta-cells in the pancreas and the MIN6 beta-cell line. Histochem Cell Biol 2012, 138:933-944.
- [25]Osmond RI, Martin-Harris MH, Crouch MF, Park J, Morreale E, Dupriez VJ: G-protein-coupled receptor-mediated MAPK and PI3-kinase signaling is maintained in Chinese hamster ovary cells after gamma-irradiation. J Biomol Screen 2012, 17:361-369.
- [26]Zambad SP, Tuli D, Mathur A, Ghalsasi SA, Chaudhary AR, Deshpande S, Gupta RC, Chauthaiwale V, Dutt C: TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes Metab Syndr Obes 2013, 7:1-14.
- [27]Cheng K, Delghingaro-Augusto V, Nolan CJ, Turner N, Hallahan N, Andrikopoulos S, Gunton JE: High passage MIN6 cells have impaired insulin secretion with impaired glucose and lipid oxidation. PLoS One 2012, 7:e40868.
- [28]Lee PY, Chen W, Liu IM, Cheng JT: Vasodilatation induced by sinomenine lowers blood pressure in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2007, 34:979-984.
- [29]Chan SL, Mourtada M, Morgan NG: Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Diabetes 2001, 50:340-347.
- [30]Mourtada M, Chan SL, Smith SA, Morgan NG: Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets. Br J Pharmacol 1999, 127:1279-1287.
- [31]Bleck C, Wienbergen A, Rustenbeck I: Essential role of the imidazoline moiety in the insulinotropic effect but not the KATP channel-blocking effect of imidazolines; a comparison of the effects of efaroxan and its imidazole analogue, KU14R. Diabetologia 2005, 48:2567-2575.
- [32]Mayer G, Taberner PV: Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Eur J Pharmacol 2002, 454:95-102.
- [33]Kahn LP, Nolan JV: Kinetics of allantoin metabolism in sheep. Br J Nutr 2000, 84:629-634.
- [34]Pak N, Donoso G, Tagle MA: Allantoin excretion in the rat. Br J Nutr 1973, 30:107-112.
- [35]Koguchi T, Nakajima H, Wada M, Yamamoto Y, Innami S, Maekawa A, Tadokor T: Dietary fiber suppresses elevations of uric acid and allantoin in serum and urine induced by dietary RNA and increases its excretion to feces in rats. J Nutr Sci Vitaminol (Tokyo) 2002, 48:184-193.
- [36]Nebieridze DV, Kamyshova TV: Imidazoline receptor agonists: are they actual today? Kardiologiia 2012, 52:90-93.
- [37]Tanabe M: Imidazoline receptor. Nihon Yakurigaku Zasshi 2008, 131:478-480.
- [38]Zhang J, Abdel-Rahman AA: Nischarin as a functional imidazoline (I1) receptor. FEBS Lett 2006, 580:3070-3074.
- [39]Chung HH, Lee KS, Cheng JT: Decrease of obesity by allantoin via imidazoline I 1 -receptor activation in high fat diet-fed mice. Evid Based Complement Alternat Med 2013, 2013:589309.
- [40]Yang TT, Chiu NH, Chung HH, Hsu CT, Lee WJ, Cheng JT: Stimulatory effect of allantoin on imidazoline I(1) receptors in animal and cell line. Horm Metab Res 2012, 44:879-884.
- [41]Chen MF, Yang TT, Yeh LR, Chung HH, Wen YJ, Lee WJ, Cheng JT: Activation of imidazoline I-2B receptors by allantoin to increase glucose uptake into C(2)C(1)(2) cells. Horm Metab Res 2012, 44:268-272.
- [42]Lin KC, Yeh LR, Chen LJ, Wen YJ, Cheng KC, Cheng JT: Plasma glucose-lowering action of allantoin is induced by activation of imidazoline I-2 receptors in streptozotocin-induced diabetic rats. Horm Metab Res 2012, 44:41-46.
- [43]Marigo V, Courville K, Hsu WH, Feng JM, Cheng H: TRPM4 impacts on Ca2+ signals during agonist-induced insulin secretion in pancreatic beta-cells. Mol Cell Endocrinol 2009, 299:194-203.
- [44]Ali MY, Whiteman M, Low CM, Moore PK: Hydrogen sulphide reduces insulin secretion from HIT-T15 cells by a KATP channel-dependent pathway. J Endocrinol 2007, 195:105-112.
- [45]Tominaga M, Horie M, Sasayama S, Okada Y: Glibenclamide, an ATP-sensitive K + channel blocker, inhibits cardiac cAMP-activated Cl- conductance. Circ Res 1995, 77:417-423.
- [46]Chan SL, Brown CA, Scarpello KE, Morgan NG: The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites. Br J Pharmacol 1994, 112:1065-1070.
- [47]Chen MF, Tsai JT, Chen LJ, Wu TP, Yang JJ, Yin LT, Yang YL, Chiang TA, Lu HL, Wu MC: Antihypertensive action of allantoin in animals. Biomed Res Int 2014, 2014:690135.
- [48]Chung HH, Cheng J: Improvement of obesity by activation of I1-imidazoline receptors in high fat diet-fed mice. Horm Metab Res 2013, 45:581-585.